Shares of RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) were down 7.7% on Wednesday . The company traded as low as $9.93 and last traded at $9.93. Approximately 500 shares were traded during trading, a decline of 17% from the average daily volume of 600 shares. The stock had previously closed at $10.7550.
RemeGen Stock Performance
The firm’s 50 day simple moving average is $11.63 and its 200-day simple moving average is $7.36.
RemeGen Company Profile
RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.
Featured Stories
- Five stocks we like better than RemeGen
- Best Stocks Under $10.00
- Market Momentum: 3 Stocks Poised for Major Breakouts
- How to Calculate Return on Investment (ROI)
- 3 Reasons Casey’s General Stores Will Continue Trending Higher
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Golden Cross Alert: 3 Stocks With Major Upside Potential
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
